Our Services
Medical Information
Helpful Resources
Published on: 2/28/2026
Dapagliflozin is generally safe and proven to help type 2 diabetes, heart failure, and kidney disease, but it commonly causes increased urination, thirst, and genital yeast infections and can rarely trigger serious issues like ketoacidosis, severe dehydration, kidney problems, or a dangerous genital infection.
There are several factors to consider for your next steps, such as staying hydrated, monitoring sugars, and calling your clinician urgently for severe or persistent symptoms while not stopping the drug on your own; see below for complete guidance, red flags, and who needs extra caution.
If you've recently started dapagliflozin and noticed changes in your body, you may be wondering: Is dapagliflozin safe? The short answer is yes—for most people, dapagliflozin is considered safe and effective when prescribed appropriately. However, like all medications, it can cause side effects. Understanding what's normal, what's concerning, and what to do next can help you stay safe and confident in your treatment plan.
Let's break it down clearly and calmly.
Dapagliflozin is a prescription medication used to treat:
It belongs to a class of drugs called SGLT2 inhibitors. These medications work by helping your kidneys remove excess glucose (sugar) from your body through urine. By lowering blood sugar levels, dapagliflozin can:
Major clinical trials and regulatory agencies have found dapagliflozin to be generally safe when used correctly. But your body may react in ways that feel unfamiliar.
Because dapagliflozin changes how your kidneys process glucose, it alters your body's fluid balance and urinary patterns. Some reactions are expected and usually mild.
These are typically not dangerous but should still be monitored:
Why do these happen?
For many people, these effects lessen as the body adjusts.
While uncommon, there are risks you should not ignore.
This is rare but serious. It can occur even if blood sugar is not extremely high.
Watch for:
If these symptoms appear, seek medical care immediately.
Dapagliflozin increases urination. If fluid intake is too low, you may develop:
Older adults and people on diuretics are at higher risk.
Although dapagliflozin protects kidney function long-term, some people may experience temporary changes in kidney lab values.
Call your doctor if you notice:
A rare but serious infection of the genital area has been reported with SGLT2 inhibitors.
Seek urgent medical care for:
This is extremely uncommon, but prompt treatment is critical.
Large clinical trials involving thousands of patients have shown that dapagliflozin reduces the risk of heart failure hospitalization and slows kidney disease progression. For many patients, the long-term benefits outweigh the risks.
Safety depends on:
It's important to remember that untreated diabetes itself carries serious risks, including:
In many cases, dapagliflozin helps reduce those risks.
Sometimes symptoms blamed on dapagliflozin are actually related to underlying diabetes.
High blood sugar can cause:
If you're unsure whether your symptoms are medication-related or due to uncontrolled blood sugar, you can use a free AI-powered Diabetes Mellitus symptom checker to quickly assess what might be causing your symptoms and whether you should speak with your doctor right away.
Dapagliflozin may require careful monitoring if you:
Always inform your doctor about:
Temporary discontinuation may be needed during illness or surgery.
Here are practical next steps:
Mild symptoms (like increased urination or mild yeast infection) can often be managed.
Severe symptoms (vomiting, confusion, fainting, intense pain) require urgent care.
Drink adequate water unless your doctor has restricted fluids. This helps prevent:
Check levels as recommended. Unexpected changes could indicate:
Call your healthcare provider if you experience:
Do not stop dapagliflozin abruptly without medical advice unless symptoms are life-threatening.
Do not discontinue dapagliflozin on your own unless directed by a healthcare professional.
Stopping suddenly can:
If side effects are intolerable, your doctor can:
There are many diabetes treatment options available. You are not "stuck" with one medication.
For most people, dapagliflozin is safe and beneficial, especially for managing Type 2 diabetes, heart failure, and kidney disease. It has strong evidence supporting its use.
However:
Your body reacting does not automatically mean the medication is dangerous. It may mean adjustments are needed.
Go to urgent care or the emergency room if you experience:
These situations can be life-threatening and require immediate evaluation.
Managing diabetes and related conditions is a long-term journey. Medications like dapagliflozin are tools designed to reduce serious health risks, not create them. Most reactions are manageable, but awareness is key.
If you are experiencing symptoms or feel unsure about your diagnosis, consider starting with a free online Diabetes Mellitus symptom checker and then speak directly with a doctor.
Most importantly:
If you have symptoms that could be serious or life-threatening, speak to a doctor immediately. Do not delay medical care.
Your safety always comes first.
(References)
* Wiviott SD, Raz I, Bonaca MS, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
* Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 22;383(15):1436-1446. doi: 10.1056/NEJMoa2024884. Epub 2020 Sep 24. PMID: 32970396.
* McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 1. PMID: 31479280.
* Nauck MA, Berhanu P, Bloomgarden ZT, et al. Dapagliflozin and the risk of diabetic ketoacidosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022 Jul;24(7):1380-1390. doi: 10.1111/dom.14713. Epub 2022 May 25. PMID: 35501861.
* Alabdan NA, Alshehri AM, Alharbi MS, et al. Safety Profile of Sodium Glucose Co-transporter-2 (SGLT2) Inhibitors: A Comprehensive Review. Cureus. 2023 Mar 1;15(3):e35626. doi: 10.7759/cureus.35626. PMID: 37007138; PMCID: PMC10065091.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.